Dennis O'Brien

Dennis O'Brien, MD, MBA is currently the Vice President and Head of Drug Safety and Pharmacovigilance at Syndax Pharmaceuticals since September 2022. Prior to this, they held various roles at Boehringer Ingelheim, including Executive Director in the Therapeutic Area Head Risk Management Oncology and Biosimilars from February 2018 to October 2022, Executive Director in the Therapeutic Area Head Oncology Risk Management from August 2013 to September 2022, Director from August 2011 to August 2013, and Senior Associate Director from March 2009 to August 2011. Dennis also worked as an Associate Director at Takeda Pharmaceuticals from February 2006 to February 2009.

Dennis O'Brien, MD, MBA, holds a Doctor of Medicine (M.D.) degree from the University of Missouri-Columbia. Dennis also obtained a Master of Business Administration (M.B.A.) from the University of South Florida. Additionally, they completed their undergraduate studies at Rockhurst University, earning a Bachelor of Science (BS) degree in Biology, General.